C280 Intimin and EspB are Promising Antigens for the Stimulation of Mucosal Immune Responses against EHEC.

CATALDI A; YEVSA T; VILTE DA,; CASTRO PARODI M; SCHULZE K; LARZÁBAL M; IBARRA C; MERCADO EC; GUZMÁN CA

Melbourne

Congreso; VTEC2006; 2006

  Mucosal vaccine formulations based on purified recombinant intimin, EspA, EspB or and Stx2B from enterohemorragic Escherichia coli co-administered with the TLR2/6 agonist MALP-2 as adjuvant were evaluated in BALB/c mice by intranasal inoculation. After intranasal vaccination, a A significative increase in strong humoral and cellular immune responses were observed against C280- gamma intimin and EspB were achieved with the incorporation of MALP-2 in vaccinal formulations, whereas weak responses increase were detected observed using EspA- and Stx2B-based formulations. Antigen-specific T-cell proliferation, IL-2 and IFN-alpha producing cells and secretory IgA were only detected in animals receiving MALP-2 (mycoplasmal macrophage activating lipopeptide-2) as adjuvant. In contrast, the administration of antigens by the conjunctival route resulted in poor responses. These results suggest that C280 gamma- intimin and EspB are good candidate antigens to be incorporated into mucosal vaccines against this important pathogen.